Yahoo Finance

GE HealthCare’s manganese-based MRI contrast agent shines in Phase I trial

GE HealthCare has announced positive results from a Phase I study of its manganese-based macrocyclic magnetic resonance imaging (MRI) contrast agent. Data from the first-in-human trial – presented at ...
pharmaphorum

Positive new phase 3 MRI data from UPLIZNA trial for NMOSD

Horizon Therapeutics Plc presented positive new MRI data from the phase 3 clinical trial of UPLIZNA (inebilizumab) at the 9th Congress of the European Academy of Neurology (EAN) in Budapest, showing a ...
Business Wire

GE HealthCare Announces Completion of Phase I Subject Recruitment in Early Clinical Development Program for a First-of-its-Kind Macrocyclic Manganese-Based MRI Contrast Agent

Novel manganese-based macrocyclic Magnetic Resonance Imaging (MRI) agent could offer an alternative to gadolinium-based agents Manganese is a trace element naturally occurring in, and efficiently ...
EurekAlert!

Contrast-enhanced in-phase Dixon sequence impacts biopsy clip detection on breast MRI

Leesburg, VA, September 14, 2022—According to ARRS’ American Journal of Roentgenology (AJR), the contrast-enhanced in-phase Dixon sequence could reduce the need for correlation among other imaging ...